no Art

L Number	Hits	Search Text	DB	Time stamp
1	123777	brain or nerve or neurological or (nervous adj system)	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/01/25 17:24
7	601578	development or developmental	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/01/25 17:25
13	686797	(brain or nerve or neurological or (nervous adj system)) or (development or developmental)	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/01/25 17:25
19	38558	(brain or nerve or neurological or (nervous adj system)) and (development or developmental)	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/01/25 17:26
25	3615	((brain or nerve or neurological or (nervous adj system)) and (development or developmental)) and (cell near2 adhesion)	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/01/25 17:27
31	229975	gene or (nucleic adj acid) or clone	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/01/25 17:30
37	15174	(gene or (nucleic adj acid) or clone) near4 (disorder or disease or pathology)	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/01/25 17:31
43	1103	(((brain or nerve or neurological or (nervous adj system)) and (development or developmental)) and (cell near2 adhesion)) and ((gene or (nucleic adj acid) or clone) near4 (disorder or disease or pathology))	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/01/25 17:34
49	1	((((brain or nerve or neurological or (nervous adj system)) and (development or developmental)) and (cell near2 adhesion)) and ((gene or (nucleic adj acid) or clone) near4 (disorder or disease or pathology))) and (limulus adj factor adj c)	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/01/25 17:35

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1653sxs

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2	Apr 08	"Ask CAS" for self-help around the clock
NEWS 3	Apr 09	BEILSTEIN: Reload and Implementation of a New Subject Area
NEWS 4	Apr 09	ZDB will be removed from STN
NEWS 5	Apr 19	US Patent Applications available in IFICDB, IFIPAT, and IFIUDB
NEWS 6	Apr 22	Records from IP.com available in CAPLUS, HCAPLUS, and ZCAPLUS
NEWS 7	Apr 22	BIOSIS Gene Names now available in TOXCENTER
NEWS 8	Apr 22	Federal Research in Progress (FEDRIP) now available
NEWS 9	Jun 03	New e-mail delivery for search results now available
NEWS 10	Jun 10	MEDLINE Reload
NEWS 11	Jun 10	PCTFULL has been reloaded
NEWS 12	Jul 02	FOREGE no longer contains STANDARDS file segment
NEWS 13	Jul 22	USAN to be reloaded July 28, 2002; saved answer sets no longer valid
NEWS 14	Jul 29	Enhanced polymer searching in REGISTRY
NEWS 15	Jul 30	NETFIRST to be removed from STN
NEWS 16	Aug 08	CANCERLIT reload
NEWS 17	Aug 08	PHARMAMarketLetter(PHARMAML) - new on STN
NEWS 18	Aug 08	NTIS has been reloaded and enhanced
NEWS 19	Aug 19	Aquatic Toxicity Information Retrieval (AQUIRE) now available on STN
NEWS 20	Aug 19	IFIPAT, IFICDB, and IFIUDB have been reloaded
NEWS 21	Aug 19	The MEDLINE file segment of TOXCENTER has been reloaded
NEWS 22	Aug 26	Sequence searching in REGISTRY enhanced
NEWS 23	Sep 03	JAPIO has been reloaded and enhanced
NEWS 24	Sep 16	Experimental properties added to the REGISTRY file
NEWS 25	Sep 16	CA Section Thesaurus available in CAPLUS and CA
NEWS 26	Oct 01	CASREACT Enriched with Reactions from 1907 to 1985
NEWS 27	Oct 21	EVENTLINE has been reloaded
NEWS 28	Oct 24	BEILSTEIN adds new search fields
NEWS 29	Oct 24	Nutraceuticals International (NUTRACEUT) now available on STN
NEWS 30	Oct 25	MEDLINE SDI run of October 8, 2002
NEWS 31	Nov 18	DKILIT has been renamed APOLLIT
NEWS 32	Nov 25	More calculated properties added to REGISTRY
NEWS 33	Dec 02	TIBKAT will be removed from STN
NEWS 34	Dec 04	CSA files on STN
NEWS 35	Dec 17	PCTFULL now covers WP/PCT Applications from 1978 to date
NEWS 36	Dec 17	TOXCENTER enhanced with additional content
NEWS 37	Dec 17	Adis Clinical Trials Insight now available on STN
NEWS 38	Dec 30	ISMEC no longer available
NEWS 39	Jan 13	Indexing added to some pre-1967 records in CA/CAPLUS
NEWS 40	Jan 21	NUTRACEUT offering one free connect hour in February 2003
NEWS 41	Jan 21	PHARMAML offering one free connect hour in February 2003

NEWS EXPRESS January 6 CURRENT WINDOWS VERSION IS V6.01a,
CURRENT MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP),

```
                AND CURRENT DISCOVER FILE IS DATED 01 OCTOBER 2002
NEWS HOURS      STN Operating Hours Plus Help Desk Availability
NEWS INTER      General Internet Information
NEWS LOGIN      Welcome Banner and News Items
NEWS PHONE      Direct Dial and Telecommunication Network Access to STN
NEWS WWW        CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

  * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * *



FILE 'HOME' ENTERED AT 17:39:07 ON 25 JAN 2003

=> File bioscience health medicine meetings pharmacology research toxicology
FILE 'DRUGMONOG' ACCESS NOT AUTHORIZED
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     0.21       0.21

FILE 'ADISCTI' ENTERED AT 17:39:30 ON 25 JAN 2003
COPYRIGHT (C) 2003 Adis International Ltd. (ADIS)

FILE 'ADISINSIGHT' ENTERED AT 17:39:30 ON 25 JAN 2003
COPYRIGHT (C) 2003 Adis International Ltd. (ADIS)

FILE 'ADISNEWS' ENTERED AT 17:39:30 ON 25 JAN 2003
COPYRIGHT (C) 2003 Adis International Ltd. (ADIS)

FILE 'AGRICOLA' ENTERED AT 17:39:30 ON 25 JAN 2003

FILE 'ANABSTR' ENTERED AT 17:39:30 ON 25 JAN 2003
COPYRIGHT (c) 2003 THE ROYAL SOCIETY OF CHEMISTRY (RSC)

FILE 'AQUASCI' ENTERED AT 17:39:30 ON 25 JAN 2003
(c) 2003 FAO (on behalf of the ASFA Advisory Board) All rights reserved.

FILE 'BIOBUSINESS' ENTERED AT 17:39:30 ON 25 JAN 2003
COPYRIGHT (C) 2003 Biological Abstracts, Inc. (BIOSIS)

FILE 'BIOCOMMERCE' ENTERED AT 17:39:30 ON 25 JAN 2003
COPYRIGHT (C) 2003 BioCommerce Data Ltd. Richmond Surrey, United Kingdom. All
rights reserved

FILE 'BIOSIS' ENTERED AT 17:39:30 ON 25 JAN 2003
COPYRIGHT (C) 2003 BIOLOGICAL ABSTRACTS INC.(R)

FILE 'BIOTECHABS' ENTERED AT 17:39:30 ON 25 JAN 2003
COPYRIGHT (C) 2003 THOMSON DERWENT AND INSTITUTE FOR SCIENTIFIC INFORMATION

FILE 'BIOTECHDS' ACCESS NOT AUTHORIZED

FILE 'BIOTECHNO' ENTERED AT 17:39:30 ON 25 JAN 2003
```

FILE 'CABA' ENTERED AT 17:39:30 ON 25 JAN 2003

FILE 'CANCERLIT' ENTERED AT 17:39:30 ON 25 JAN 2003

FILE 'CAPLUS' ENTERED AT 17:39:30 ON 25 JAN 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE 'CEABA-VTB' ENTERED AT 17:39:30 ON 25 JAN 2003

FILE 'CEN' ENTERED AT 17:39:30 ON 25 JAN 2003

FILE 'CIN' ENTERED AT 17:39:30 ON 25 JAN 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE 'CONFSCI' ENTERED AT 17:39:30 ON 25 JAN 2003

FILE 'CROPB' ENTERED AT 17:39:30 ON 25 JAN 2003

FILE 'CROPU' ENTERED AT 17:39:30 ON 25 JAN 2003

FILE 'DDFB' ENTERED AT 17:39:30 ON 25 JAN 2003

FILE 'DDFU' ENTERED AT 17:39:30 ON 25 JAN 2003

FILE 'DGENE' ENTERED AT 17:39:30 ON 25 JAN 2003

FILE 'DRUGB' ACCESS NOT AUTHORIZED

FILE 'DRUGLAUNCH' ENTERED AT 17:39:30 ON 25 JAN 2003

FILE 'DRUGMONOG2' ENTERED AT 17:39:30 ON 25 JAN 2003

FILE 'DRUGNL' ENTERED AT 17:39:30 ON 25 JAN 2003

FILE 'DRUGU' ACCESS NOT AUTHORIZED

FILE 'DRUGUPDATES' ENTERED AT 17:39:30 ON 25 JAN 2003

FILE 'EMBAL' ENTERED AT 17:39:30 ON 25 JAN 2003

FILE 'EMBASE' ENTERED AT 17:39:30 ON 25 JAN 2003

FILE 'ESBIOBASE' ENTERED AT 17:39:30 ON 25 JAN 2003

FILE 'FEDRIP' ENTERED AT 17:39:30 ON 25 JAN 2003

FILE 'FOMAD' ENTERED AT 17:39:30 ON 25 JAN 2003

FILE 'FOREGE' ENTERED AT 17:39:30 ON 25 JAN 2003

FILE 'FROSTI' ENTERED AT 17:39:30 ON 25 JAN 2003

FILE 'FSTA' ENTERED AT 17:39:30 ON 25 JAN 2003

FILE 'GENBANK' ENTERED AT 17:39:30 ON 25 JAN 2003

FILE 'HEALSAFE' ENTERED AT 17:39:30 ON 25 JAN 2003

FILE 'IFIPAT' ENTERED AT 17:39:30 ON 25 JAN 2003

FILE 'JICST-EPLUS' ENTERED AT 17:39:30 ON 25 JAN 2003

FILE 'KOSMET' ENTERED AT 17:39:30 ON 25 JAN 2003

FILE 'LIFESCI' ENTERED AT 17:39:30 ON 25 JAN 2003

FILE 'MEDICONF' ENTERED AT 17:39:30 ON 25 JAN 2003

FILE 'MEDLINE' ENTERED AT 17:39:30 ON 25 JAN 2003

FILE 'NIOSHTIC' ENTERED AT 17:39:30 ON 25 JAN 2003

FILE 'NTIS' ENTERED AT 17:39:30 ON 25 JAN 2003

FILE 'OCEAN' ENTERED AT 17:39:30 ON 25 JAN 2003

FILE 'PASCAL' ENTERED AT 17:39:30 ON 25 JAN 2003

FILE 'PHAR' ENTERED AT 17:39:30 ON 25 JAN 2003

FILE 'PHARMAML' ENTERED AT 17:39:30 ON 25 JAN 2003

FILE 'PHIC' ENTERED AT 17:39:30 ON 25 JAN 2003

FILE 'PHIN' ENTERED AT 17:39:30 ON 25 JAN 2003

FILE 'PROMT' ENTERED AT 17:39:30 ON 25 JAN 2003

FILE 'SCISEARCH' ENTERED AT 17:39:30 ON 25 JAN 2003

FILE 'SYNTHLINE' ENTERED AT 17:39:30 ON 25 JAN 2003

FILE 'TOXCENTER' ENTERED AT 17:39:30 ON 25 JAN 2003

FILE 'USPATFULL' ENTERED AT 17:39:30 ON 25 JAN 2003

FILE 'USPAT2' ENTERED AT 17:39:30 ON 25 JAN 2003

FILE 'VETB' ENTERED AT 17:39:30 ON 25 JAN 2003

FILE 'VETU' ENTERED AT 17:39:30 ON 25 JAN 2003

FILE 'WPIDS' ACCESS NOT AUTHORIZED

FILE 'WPINDEX' ENTERED AT 17:39:30 ON 25 JAN 2003

FILE 'CBNB' ENTERED AT 17:39:30 ON 25 JAN 2003

FILE 'CHEMLIST' ENTERED AT 17:39:30 ON 25 JAN 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE 'CSNB' ENTERED AT 17:39:30 ON 25 JAN 2003

FILE 'ENERGY' ENTERED AT 17:39:30 ON 25 JAN 2003

FILE 'HSDB' ENTERED AT 17:39:30 ON 25 JAN 2003

FILE 'INIS' ACCESS NOT AUTHORIZED

FILE 'IPA' ENTERED AT 17:39:30 ON 25 JAN 2003

FILE 'MSDS-CCOHS' ENTERED AT 17:39:30 ON 25 JAN 2003

FILE 'MSDS-OHS' ENTERED AT 17:39:30 ON 25 JAN 2003

FILE 'NAPRALERT' ENTERED AT 17:39:30 ON 25 JAN 2003

FILE 'NLDB' ENTERED AT 17:39:30 ON 25 JAN 2003

FILE 'POLLUAB' ENTERED AT 17:39:30 ON 25 JAN 2003

FILE 'RTECS' ENTERED AT 17:39:30 ON 25 JAN 2003

FILE '1MOBILITY' ENTERED AT 17:39:30 ON 25 JAN 2003

FILE 'COMPENDEX' ENTERED AT 17:39:30 ON 25 JAN 2003

FILE 'COMPUAB' ENTERED AT 17:39:30 ON 25 JAN 2003

FILE 'CONF' ENTERED AT 17:39:30 ON 25 JAN 2003

FILE 'ELCOM' ENTERED AT 17:39:30 ON 25 JAN 2003

FILE 'EVENTLINE' ENTERED AT 17:39:30 ON 25 JAN 2003

FILE 'IMSDRUGCONF' ENTERED AT 17:39:30 ON 25 JAN 2003

FILE 'PAPERCHEM2' ENTERED AT 17:39:30 ON 25 JAN 2003

FILE 'SOLIDSTATE' ENTERED AT 17:39:30 ON 25 JAN 2003

FILE 'BABS' ENTERED AT 17:39:30 ON 25 JAN 2003

FILE 'DIOGENES' ENTERED AT 17:39:30 ON 25 JAN 2003

FILE 'INVESTEXT' ENTERED AT 17:39:30 ON 25 JAN 2003

FILE 'USAN' ENTERED AT 17:39:30 ON 25 JAN 2003

COPYRIGHT (C) 2003 U.S. Pharmacopeial Convention, Inc. (USPC)

FILE 'DKF' ENTERED AT 17:39:30 ON 25 JAN 2003
COPYRIGHT (C) 2003 Dokumentation Kraftfahrwesen e.V., Germany

FILE 'FORIS' ENTERED AT 17:39:30 ON 25 JAN 2003
COPYRIGHT (C) 2003 Informationszentrum Sozialwissenschaften, Bonn (IZS)

FILE 'FORKAT' ENTERED AT 17:39:30 ON 25 JAN 2003
COPYRIGHT (C) 2003 Bundesministerium fuer Bildung,
Wissenschaft, Forschung und Technologie (bmb+f)

FILE 'RUSSCI' ENTERED AT 17:39:30 ON 25 JAN 2003
COPYRIGHT (C) 2003 Andrigal Ltd.

FILE 'SOLIS' ENTERED AT 17:39:30 ON 25 JAN 2003
COPYRIGHT (C) 2003 Informationszentrum Sozialwissenschaften, Bonn (IZS)

FILE 'UFORDAT' ENTERED AT 17:39:30 ON 25 JAN 2003
COPYRIGHT (C) 2003 Umweltbundesamt, D-14191 Berlin (UBA)

FILE 'AQUIRE' ENTERED AT 17:39:30 ON 25 JAN 2003
COPYRIGHT (C) 2003 US Environmental Protection Agency (EPA)

FILE 'ULIDAT' ENTERED AT 17:39:30 ON 25 JAN 2003
COPYRIGHT (C) 2003 Umweltbundesamt, D-14191 Berlin (UBA)

=> s brain or nerve or neurologica or (nervous system)
    9 FILES SEARCHED...
   22 FILES SEARCHED...
   29 FILES SEARCHED...
   37 FILES SEARCHED...
   43 FILES SEARCHED...
<------User Break------>

SEARCH ENDED BY USER
   47 FILES SEARCHED...
SEARCH ENDED BY USER

=>
<------User Break------>

=> s brain or nerve or neuronal or neurological or (nervous system)
    9 FILES SEARCHED...
   22 FILES SEARCHED...
   27 FILES SEARCHED...
   30 FILES SEARCHED...
   39 FILES SEARCHED...
   46 FILES SEARCHED...
   52 FILES SEARCHED...
   59 FILES SEARCHED...
   67 FILES SEARCHED...
   74 FILES SEARCHED...
L1   10583595 BRAIN OR NERVE OR NEURONAL OR NEUROLOGICAL OR (NERVOUS SYSTEM)

=> s development or developmental
   20 FILES SEARCHED...
   42 FILES SEARCHED...
   52 FILES SEARCHED...
   74 FILES SEARCHED...
COMMAND INTERRUPTED
If this message appears repeatedly, please notify the Help Desk.

```
Enter "HELP STN" for information on contacting the nearest STN Help
Desk by telephone or via SEND in the STNMAIL file.

=> s cell (2A) adhesion
  11 FILES SEARCHED...
  13 FILES SEARCHED...
  28 FILES SEARCHED...
  34 FILES SEARCHED...
  47 FILES SEARCHED...
  60 FILES SEARCHED...
  91 FILES SEARCHED...
L2      355977 CELL (2A) ADHESION

=> s l1 and l2
  30 FILES SEARCHED...
  68 FILES SEARCHED...
L3       54272 L1 AND L2

=> s l3 and (development or developmental)
  30 FILES SEARCHED...
  56 FILES SEARCHED...
  89 FILES SEARCHED...
L4       20259 L3 AND (DEVELOPMENT OR DEVELOPMENTAL)

=> s l4 and (gene or (nucleic acid) or DNA or clone)
  11 FILES SEARCHED...
  14 FILES SEARCHED...
  23 FILES SEARCHED...
  31 FILES SEARCHED...
  36 FILES SEARCHED...
  43 FILES SEARCHED...
  53 FILES SEARCHED...
  56 FILES SEARCHED...
  61 FILES SEARCHED...
  78 FILES SEARCHED...
L5        8854 L4 AND (GENE OR (NUCLEIC ACID) OR DNA OR CLONE)

=> l5 and (disorder or disease or pathology)
L5 IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> s l5 and (disorder or disease or pathology)
  10 FILES SEARCHED...
  22 FILES SEARCHED...
  23 FILES SEARCHED...
  39 FILES SEARCHED...
  47 FILES SEARCHED...
  61 FILES SEARCHED...
  92 FILES SEARCHED...
L6        4360 L5 AND (DISORDER OR DISEASE OR PATHOLOGY)

=> s l6 and (limulus adj factor adj c)
  17 FILES SEARCHED...
  33 FILES SEARCHED...
  51 FILES SEARCHED...
  69 FILES SEARCHED...
L7           0 L6 AND (LIMULUS ADJ FACTOR ADJ C)

=> s l6 and (limulus or Lccl)
  45 FILES SEARCHED...
```

```
  90 FILES SEARCHED...
 75% OF LIMIT FOR L#S REACHED
L8          37 L6 AND (LIMULUS OR LCCL)

=> duplicate
ENTER REMOVE, IDENTIFY, ONLY, OR (?):remove
ENTER L# LIST OR (END):l8
DUPLICATE IS NOT AVAILABLE IN 'ADISINSIGHT, ADISNEWS, BIOCOMMERCE, DGENE,
DRUGLAUNCH, DRUGMONOG2, DRUGUPDATES, FEDRIP, FOREGE, GENBANK, KOSMET,
MEDICONF, PHAR, PHARMAML, SYNTHLINE, CHEMLIST, HSDB, MSDS-CCOHS, MSDS-OHS,
RTECS, CONF, EVENTLINE, IMSDRUGCONF, DIOGENES, INVESTEXT, USAN, FORIS, FORKAT,
UFORDAT, AQUIRE'.
ANSWERS FROM THESE FILES WILL BE CONSIDERED UNIQUE
PROCESSING COMPLETED FOR L8
L9           37 DUPLICATE REMOVE L8 (0 DUPLICATES REMOVED)

=> d l8  1-37 bib ab

L8   ANSWER 1 OF 37  USPATFULL
AN     2002:346979  USPATFULL
TI     Composition for the detection of signaling pathway gene
       expression
IN     Au-Young, Janice, Berkeley, CA, United States
       Seilhamer, Jeffrey J., Los Altos Hills, CA, United States
PA     Incyte Genomics, Inc., Palo Alto, CA, United States (U.S. corporation)
PI     US 6500938          B1   20021231
AI     US 1998-16434            19980130 (9)
DT     Utility
FS     GRANTED
EXNAM  Primary Examiner: Marschel, Ardin H.
LREP   Incyte Genomics, Inc.
CLMN   Number of Claims: 5
ECL    Exemplary Claim: 1
DRWN   0 Drawing Figure(s); 0 Drawing Page(s)
LN.CNT 6180
AB     The present invention relates to a composition comprising a plurality of
       polynucleotide probes. The composition can be used as array elements in
       a microarray. The present invention also relates to a method for
       selecting polynucleotide probes of the composition.

L8   ANSWER 2 OF 37  USPATFULL
AN     2002:323085  USPATFULL
TI     Compositions and methods for the therapy and diagnosis of prostate
       cancer
IN     Xu, Jiangchun, Bellevue, WA, UNITED STATES
       Dillon, Davin C., Issaquah, WA, UNITED STATES
       Mitcham, Jennifer L., Redmond, WA, UNITED STATES
       Harlocker, Susan L., Seattle, WA, UNITED STATES
       Jiang, Yuqiu, Kent, WA, UNITED STATES
       Kalos, Michael D., Seattle, WA, UNITED STATES
       Fanger, Gary R., Mill Creek, WA, UNITED STATES
       Retter, Marc W., Carnation, WA, UNITED STATES
       Stolk, John A., Bothell, WA, UNITED STATES
       Day, Craig H., Shoreline, WA, UNITED STATES
       Vedvick, Thomas S., Federal Way, WA, UNITED STATES
       Carter, Darrick, Seattle, WA, UNITED STATES
       Li, Samuel X., Redmond, WA, UNITED STATES
       Wang, Aijun, Issaquah, WA, UNITED STATES
       Skeiky, Yasir A.W., Bellevue, WA, UNITED STATES
       Hepler, William T., Seattle, WA, UNITED STATES
       Henderson, Robert A., Edmonds, WA, UNITED STATES
       Hural, John, Bainbridge Island, WA, UNITED STATES
```

McNeill, Patricia D., Federal Way, WA, UNITED STATES
Houghton, Raymond L., Bothell, WA, UNITED STATES
Vinals y de Bassols, Carlota, Rixensart, BELGIUM
Foy, Teresa M., Federal Way, WA, UNITED STATES
Watanabe, Yoshihiro, Mercer Island, WA, UNITED STATES
Meagher, Madeleine Joy, Seattle, WA, UNITED STATES

PA Corixa Corporation, Seattle, WA, UNITED STATES, 98104 (U.S. corporation)

PI US 2002183251 A1 20021205

AI US 2001-12896 A1 20011210 (10)

RLI Continuation-in-part of Ser. No. US 2001-895814, filed on 29 Jun 2001, PENDING Continuation-in-part of Ser. No. US 2001-852911, filed on 9 May 2001, PENDING Continuation-in-part of Ser. No. US 2001-780669, filed on 9 Feb 2001, PENDING Continuation-in-part of Ser. No. US 2001-759143, filed on 12 Jan 2001, PENDING Continuation-in-part of Ser. No. US 2000-709729, filed on 9 Nov 2000, ABANDONED Continuation-in-part of Ser. No. US 2000-685166, filed on 10 Oct 2000, PENDING Continuation-in-part of Ser. No. US 2000-679426, filed on 2 Oct 2000, PENDING Continuation-in-part of Ser. No. US 2000-657279, filed on 6 Sep 2000, PENDING Continuation-in-part of Ser. No. US 2000-651236, filed on 29 Aug 2000, PENDING Continuation-in-part of Ser. No. US 2000-636215, filed on 9 Aug 2000, PENDING Continuation-in-part of Ser. No. US 2000-605783, filed on 27 Jun 2000, PENDING Continuation-in-part of Ser. No. US 2000-593793, filed on 13 Jun 2000, PENDING Continuation-in-part of Ser. No. US 2000-570737, filed on 12 May 2000, PENDING Continuation-in-part of Ser. No. US 2000-568100, filed on 9 May 2000, PENDING Continuation-in-part of Ser. No. US 2000-536857, filed on 27 Mar 2000, ABANDONED Continuation-in-part of Ser. No. US 2000-483672, filed on 14 Jan 2000, PENDING Continuation-in-part of Ser. No. US 1999-443686, filed on 18 Nov 1999, ABANDONED Continuation-in-part of Ser. No. US 1999-439313, filed on 12 Nov 1999, GRANTED, Pat. No. US 6329505 Continuation-in-part of Ser. No. US 1999-352616, filed on 13 Jul 1999, GRANTED, Pat. No. US 6395278 Continuation-in-part of Ser. No. US 1999-288946, filed on 9 Apr 1999, PENDING Continuation-in-part of Ser. No. US 1999-232149, filed on 15 Jan 1999, PENDING Continuation-in-part of Ser. No. US 1998-159812, filed on 23 Sep 1998, PENDING Continuation-in-part of Ser. No. US 1998-115453, filed on 14 Jul 1998, PENDING Continuation-in-part of Ser. No. US 1998-30607, filed on 25 Feb 1998, GRANTED, Pat. No. US 6262245 Continuation-in-part of Ser. No. US 1998-20956, filed on 9 Feb 1998, GRANTED, Pat. No. US 6261562 Continuation-in-part of Ser. No. US 1997-904804, filed on 1 Aug 1997, ABANDONED Continuation-in-part of Ser. No. US 1997-806099, filed on 25 Feb 1997, ABANDONED

DT Utility

FS APPLICATION

LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300, SEATTLE, WA, 98104-7092

CLMN Number of Claims: 17

ECL Exemplary Claim: 1

DRWN 10 Drawing Page(s)

LN.CNT 8810

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions and methods for the therapy and diagnosis of cancer, particularly prostate cancer, are disclosed. Illustrative compositions comprise one or more prostate-specific polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of **diseases**, particularly prostate cancer.

L8 ANSWER 3 OF 37 USPATFULL

AN 2002:322559 USPATFULL

TI AN IMPROVED METHOD FOR THE PRODUCTION AND PURIFICATION OF ADENOVIRAL VECTORS
IN Zhang, Shuyuan, Sugar Land, TX, UNITED STATES
Thwin, Capucine, Spring, TX, UNITED STATES
Wu, Zheng, Sugar Land, TX, UNITED STATES
Cho, Toohyon, UNITED STATES
Gallagher, Shawn, Missouri City, TX, UNITED STATES
PA Introgen Therapeutics, Inc. (U.S. corporation)
PI US 2002182723 A1 20021205
AI US 2001-880609 A1 20010612 (9)
RLI Division of Ser. No. US 1998-203078, filed on 1 Dec 1998, PENDING Continuation-in-part of Ser. No. US 1997-975519, filed on 20 Nov 1997, GRANTED, Pat. No. US 6194191
PRAI US 1996-31329P 19961120 (60)
DT Utility
FS APPLICATION
LREP Steven L. Highlander, FULBRIGHT & JAWORSKI L.L.P., Suite 2400, 600 Congress Avenue, Austin, TX, 78701
CLMN Number of Claims: 43
ECL Exemplary Claim: 1
DRWN 49 Drawing Page(s)
LN.CNT 6000
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention addresses the need to improve the yields of viral vectors when grown in cell culture systems. In particular, it has been demonstrated that for adenovirus, the use of low-medium perfusion rates in an attached cell culture system provides for improved yields. In other embodiments, the inventors have shown that there is improved Ad-p53 production witrh cells grown in serum-free conditions, and in particular in serum-free suspension culture. Also important to the increase of yields is the use of detergent lysis. Combination of these aspects of the invention permits purification of virus by a single chromatography step that results in purified virus of the same quality as preparations from double CsCl banding using an ultracentrifuge.

L8 ANSWER 4 OF 37 USPATFULL
AN 2002:280564 USPATFULL
TI Novel interleukin - 1 Hy2 materials and methods
IN Ballinger, Dennis, Menlo Park, CA, UNITED STATES
Ford, John E., San Diego, CA, UNITED STATES
Ho, Alice Suk-Yue, Palo Alto, CA, UNITED STATES
Lin, Haishan, Castro Valley, CA, UNITED STATES
Pace, Ann, Scotts Valley, CA, UNITED STATES
Mize, Nancy K., Mountain View, CA, UNITED STATES
Halley-Vicente, Dana, San Diego, CA, UNITED STATES
PI US 2002156009 A1 20021024
AI US 2001-3671 A1 20011102 (10)
PRAI US 2000-245346P 20001102 (60)
DT Utility
FS APPLICATION
LREP Sharon M. Sintich, Marshall, Gerstein & Borun, 6300 Sears Tower, 223 South Wacker Drive, Chicago, IL, 60606-6357
CLMN Number of Claims: 26
ECL Exemplary Claim: 1
DRWN 10 Drawing Page(s)
LN.CNT 9665
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides machine readable storage media comprising a three-dimensional representation of Interleukin-1 Hy2 (IL-1Hy2), useful for designing and producing modulators of its activity and IL-1 Hy2 variants, and therapeutic uses thereof. The present invention also provides novel **nucleic acids** encoding IL-1 Hy2, the

novel polypeptides encoded by these **nucleic acids** and uses of these and related products.

L8 ANSWER 5 OF 37 USPATFULL
AN 2002:279682 USPATFULL
TI Methods for treating or preventing cardiovascular **disorders** by modulating metalloprotease function
IN Chun, Miyoung, Belmont, MA, UNITED STATES
Schonbeck, Uwe, Randolph, MA, UNITED STATES
Libby, Peter, Boston, MA, UNITED STATES
PI US 2002155113 A1 20021024
AI US 2002-97683 A1 20020313 (10)
PRAI US 2001-275881P 20010313 (60)
DT Utility
FS APPLICATION
LREP LOUIS MYERS, Fish & Richardson P.C., 225 Franklin Street, Boston, MA, 02110-2804
CLMN Number of Claims: 22
ECL Exemplary Claim: 1
DRWN 4 Drawing Page(s)
LN.CNT 3485
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention is based on the finding that human atheroma-associated endothelial cells (EC), smooth muscle cells (SMC) and macrophages express insterstitial collagenase MMP-8 in vitro, as well as in atherosclerotic lesions in situ. Thus, the invention features methods of modulating the activity or expression of MMP-8 and methods of inhibiting collagen degradation, particularly type I collagen degradation. The invention also features methods of treating or preventing non-neutrophil-mediated inflammatory conditions, in particular cardiovascular **disorders** such as atherosclerosis; methods of diagnosing and staging such conditions; and methods of evaluating the efficacy of a treatment for such conditions. Finally, the invention features methods of identifying agents that inhibit MMP-8 expression or activity, which can be used for the treatment of non-neutrophil-mediated inflammatory **disorders**.

L8 ANSWER 6 OF 37 USPATFULL
AN 2002:272466 USPATFULL
TI Compositions and methods for the therapy and diagnosis of breast cancer
IN Jiang, Yuqiu, Kent, WA, UNITED STATES
Dillon, Davin C., Issaquah, WA, UNITED STATES
Mitcham, Jennifer L., Redmond, WA, UNITED STATES
Xu, Jiangchun, Bellevue, WA, UNITED STATES
Harlocker, Susan L., Seattle, WA, UNITED STATES
Hepler, William T., Seattle, WA, UNITED STATES
Henderson, Robert A., Edmonds, WA, UNITED STATES
Fanger, Gary R., Mill Creek, WA, UNITED STATES
Vedvick, Thomas S., Federal Way, WA, UNITED STATES
McNeill, Patricia D., Federal Way, WA, UNITED STATES
Durham, Margarita, Seattle, WA, UNITED STATES
PA Corixa Corporation, Seattle, WA (U.S. corporation)
PI US 2002150581 A1 20021017
AI US 2001-7805 A1 20011207 (10)
RLI Continuation-in-part of Ser. No. US 2001-834759, filed on 13 Apr 2001, PENDING Continuation-in-part of Ser. No. US 2000-620405, filed on 20 Jul 2000, PENDING Continuation-in-part of Ser. No. US 2000-604287, filed on 22 Jun 2000, PENDING Continuation-in-part of Ser. No. US 2000-590751, filed on 8 Jun 2000, PENDING Continuation-in-part of Ser. No. US 2000-551621, filed on 17 Apr 2000, PENDING Continuation-in-part of Ser. No. US 1999-433826, filed on 3 Nov 1999, PENDING Continuation-in-part of Ser. No. US 1999-389681, filed on 2 Sep 1999, PENDING

Continuation-in-part of Ser. No. US 1999-339338, filed on 23 Jun 1999, PENDING Continuation-in-part of Ser. No. US 1999-285480, filed on 2 Apr 1999, PENDING Continuation-in-part of Ser. No. US 1998-222575, filed on 28 Dec 1998, GRANTED, Pat. No. US 6387697
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300, SEATTLE, WA, 98104-7092
CLMN Number of Claims: 19
ECL Exemplary Claim: 1
DRWN 2 Drawing Page(s)
LN.CNT 14059
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compositions and methods for the therapy and diagnosis of cancer, particularly breast cancer, are disclosed. Illustrative compositions comprise one or more breast tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of **diseases**, particularly breast cancer.

L8 ANSWER 7 OF 37 USPATFULL
AN 2002:268433 USPATFULL
TI Transgene expression in polarized cells
IN Eastman, Simon J., Hudson, MA, United States
Chu, Quiming, Melrose, MA, United States
Tousignant, Jennifer D., Cambridge, MA, United States
Cheng, Seng H., Wellesley, MA, United States
Scheule, Ronald K., Hopkinton, MA, United States
PA Genzyme Corporation, Framingham, MA, United States (U.S. corporation)
PI US 6465007 B1 20021015
AI US 1999-340509 19990701 (9)
PRAI US 1998-91608P 19980702 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Guzo, David
LREP Finnegan, Henderson, Farabow, Garrett & Dunner L.L.P.
CLMN Number of Claims: 16
ECL Exemplary Claim: 1
DRWN 7 Drawing Figure(s); 6 Drawing Page(s)
LN.CNT 1729
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The well-differentiated airway epithelium is the principal target tissue for **gene** therapy for the treatment of CF. However, recent studies have shown that **gene** delivery vehicles, such as cationic lipid:**DNA** complexes, can be inefficient at binding to and internalizing into polarized epithelial cells. The present invention provides a method to improve **gene** therapy by using a compound capable of disrupting tight junctions. In the practice of the invention, the transfection of a biologically active molecule by a cationic amphiphile:biologically active molecule complex or other lipid or viral or nonviral vectors is improved by treating the cells with a class of compounds known in the art as absorption enhancers or tight junction disrupting compounds.

L8 ANSWER 8 OF 37 USPATFULL
AN 2002:265535 USPATFULL
TI Regulation of human eosinophil serine protease 1- like enzyme
IN Xiao, Yonghong, Cambridge, MA, UNITED STATES
PI US 2002146407 A1 20021010
AI US 2001-885441 A1 20010621 (9)

PRAI WO 2001-EP6936 20010620
US 2000-212844P 20000621 (60)
US 2000-244171P 20001031 (60)
US 2001-279766P 20010330 (60)
DT Utility
FS APPLICATION
LREP BANNER & WITCOFF, 1001 G STREET N W, SUITE 1100, WASHINGTON, DC, 20001
CLMN Number of Claims: 66
ECL Exemplary Claim: 1
DRWN 28 Drawing Page(s)
LN.CNT 3484
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A human eosinophil serine protease 1-like enzyme, cDNA, and reagents that regulate the enzyme can play a role in preventing, ameliorating, or correcting dysfunctions or **diseases** including, but not limited to, asthma, COPD, airway allergy, and osteoporosis.

L8 ANSWER 9 OF 37 USPATFULL
AN 2002:265534 USPATFULL
TI Polypeptides with therapeutic activity and methods of use
IN Mayo, Kevin H., Minnetonka, MN, UNITED STATES
PA Regents of the University of Minnesota
PI US 2002146406 A1 20021010
AI US 2001-766353 A1 20010119 (9)
PRAI US 2000-177255P 20000120 (60)
US 2000-210297P 20000608 (60)
DT Utility
FS APPLICATION
LREP MUETING, RAASCH & GEBHARDT, P.A., P.O. BOX 581415, MINNEAPOLIS, MN, 55458
CLMN Number of Claims: 40
ECL Exemplary Claim: 1
DRWN 9 Drawing Page(s)
LN.CNT 2531
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Polypeptides and methods of use including treating bacterial infection and/or endotoxemia, decreasing the amount of TNF-.alpha., inhibiting endothelial cell proliferation, inhibiting angiogenic-factor mediated inter-cellular adhesion molecule expression down-regulation, and inhibiting angiogenesis.

L8 ANSWER 10 OF 37 USPATFULL
AN 2002:243038 USPATFULL
TI CaR receptor as a mediator of migratory cell chemotaxis and/or chemokinesis
IN Poznansky, Mark C., Charlestown, MA, UNITED STATES
Scadden, David T., Weston, MA, UNITED STATES
Olszak, Ivona T., Charlestown, MA, UNITED STATES
Brown, Edward M., Milton, MA, UNITED STATES
PI US 2002132224 A1 20020919
AI US 2001-2854 A1 20011101 (10)
RLI Continuation-in-part of Ser. No. WO 2000-US15440, filed on 2 Jun 2000, UNKNOWN
DT Utility
FS APPLICATION
LREP WOLF GREENFIELD & SACKS, PC, FEDERAL RESERVE PLAZA, 600 ATLANTIC AVENUE, BOSTON, MA, 02210-2211
CLMN Number of Claims: 84
ECL Exemplary Claim: 1
DRWN 6 Drawing Page(s)
LN.CNT 2510
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention relates to methods and compositions for modulating movement of eukaryotic cells with migratory capacity. More specifically, the invention relates to methods and compositions for modulating movement of CaR receptor expressing cells of hematopoietic, neural, epithelial, endothelial, or mesenchymal origin, in a specific site in a subject. The foregoing are useful, inter alia, in the treatment of conditions characterized by a need to modulate migratory-cell movement associated with specific sites in a subject. Specific sites include sites of inflammation and modulation of migratory-cell movement is movement away from an agent source, or repulsion. The invention also relates to methods for manipulating hematopoeitic progenitor cells and related products. In particular the invention includes methods and products for using CaR receptor-related compositions to enhance mobilization of hematopoietic progenitor cells, to improve the efficiency of targeting cells to the bone marrow, and/or to modulate hematopoietic progenitor cell function.

L8 ANSWER 11 OF 37 USPATFULL
AN 2002:227648 USPATFULL
TI Methods for treating inflammation
IN Stern, David M., Great Neck, NY, UNITED STATES
Herold, Kevan, Scarsdale, NY, UNITED STATES
Yan, Shi Du, Tenafly, NJ, UNITED STATES
Schmidt, Ann Marie, Franklin Lakes, NJ, UNITED STATES
Lamster, Ira, Wycoff, NJ, UNITED STATES
PI US 2002122799 A1 20020905
AI US 2001-872185 A1 20010601 (9)
PRAI WO 1999-US23303 19991006
DT Utility
FS APPLICATION
LREP John P. White, Cooper & Dunham, LLP, 1185 Avenue of the Americas, New York, NY, 10036
CLMN Number of Claims: 25
ECL Exemplary Claim: 1
DRWN 22 Drawing Page(s)
LN.CNT 3215
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides a method for treating inflammation in a subject which comprises administering to the subject soluble receptor for advanced glycation endproduct (sRAGE) in an amount effective to inhibit binding of advanced glycation endproducts (AGEs) to RAGE thereby treating inflammation in the subject. The present invention also provides for a method for treating inflammation in a subject which comprises administering to the subject an agent in an amount effective to inhibit the interaction between receptor for advanced glycation endproduct (RAGE) and its ligand thereby treating inflammation in the subject.

L8 ANSWER 12 OF 37 USPATFULL
AN 2002:214674 USPATFULL
TI Injectable implants for tissue augmentation and restoration
IN Urry, Dan W., Birmingham, AL, UNITED STATES
PI US 2002116069 A1 20020822
AI US 2001-841321 A1 20010423 (9)
RLI Continuation of Ser. No. US 1999-258723, filed on 26 Feb 1999, ABANDONED
PRAI US 1998-76297P 19980227 (60)
US 1998-87155P 19980529 (60)
DT Utility
FS APPLICATION
LREP COOLEY GODWARD, LLP, 3000 EL CAMINO REAL, 5 PALO ALTO SQUARE, PALO ALTO, CA, 94306
CLMN Number of Claims: 75

ECL Exemplary Claim: 1
DRWN 6 Drawing Page(s)
LN.CNT 4171
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A method for tissue augmentation in a mammal is provided comprising injecting a polymer at a tissue site in need of augmentation and having a tissue temperature, the polymer comprising repeating peptide monomeric units selected from the group consisting of nonapeptide, pentapeptide and tetrapeptide monomeric units, wherein the monomeric units form a series of .beta.-turns separated by dynamic bridging segments suspended between the .beta.-turns, wherein the polymer has an inverse temperature transition T.sub.t less than the tissue temperature, and wherein the polymer is injected as a water solution at coacervate concentration in the substantial absence of additional water. A kit containing the injectable bioelastic polymer and a syringe is also provided.

L8 ANSWER 13 OF 37 USPATFULL
AN 2002:198626 USPATFULL
TI Extracellular novel RAGE binding protein (EN-RAGE) and uses thereof
IN Schmidt, Ann Marie, Franklin Lakes, NJ, UNITED STATES
Stern, David, Great Neck, NY, UNITED STATES
PI US 2002106726 A1 20020808
AI US 2001-826589 A1 20010405 (9)
RLI Continuation of Ser. No. WO 1999-US23303, filed on 6 Oct 1999, UNKNOWN Continuation-in-part of Ser. No. US 1999-263312, filed on 5 Mar 1999, PENDING Continuation-in-part of Ser. No. US 1998-167705, filed on 6 Oct 1998, UNKNOWN
DT Utility
FS APPLICATION
LREP John P. White, Cooper & Dunham LLP, 1185 Avenue of the Americas, New York, NY, 10036
CLMN Number of Claims: 69
ECL Exemplary Claim: 1
DRWN 27 Drawing Page(s)
LN.CNT 2853
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides for an isolated human EN-RAGE peptide. The present invention also provides for a method for determining whether a compound is capable of inhibiting the interaction of an EN-RAGE peptide with a RAGE peptide, which comprises: (a) admixing: (i) a RAGE peptide or an sRAGE peptide or a fragment of either thereof, (ii) an EN-RAGE peptide or a fragment thereof, and (iii) the compound; (b) measuring the level of interaction between the peptide of step (a) (i) and the peptide of step (a) (ii), and (c) comparing the amount of interaction meausred in step (b) with the amount measured between the petpide of step (a)(i) and the peptide of step (a) (ii) in the absence of the compound/thereby determining whether the compound is capable of inhibiting the interaction of the EN-RAGE peptide with the RAGE peptide, wherein a reduction in the amount of interaction in the presence of the compound indicates that the compound is capable of inhibiting the interaction. The present invention also provides for a method for inhibiting inflammation in a subject which comprises administering to the subject a compound capable of interfering with the interaction between EN-RAGE peptide and receptor for advanced glycation endproduct (RAGE) in the subject thereby inhibiting inflammation in the subject.

L8 ANSWER 14 OF 37 USPATFULL
AN 2002:188224 USPATFULL
TI Assays involving an IL-1 receptor antagonist
IN Ford, John, San Mateo, CA, United States
Pace, Ann, Scotts Valley, CA, United States
PA Hyseq, Inc., Sunnyvale, CA, United States (U.S. corporation)

PI US 6426191 B1 20020730
AI US 1999-457626 19991208 (9)
RLI Continuation-in-part of Ser. No. US 1999-417455, filed on 13 Oct 1999, now patented, Pat. No. US 6294655 Continuation-in-part of Ser. No. US 1999-348942, filed on 7 Jul 1999, now patented, Pat. No. US 6337072 Continuation-in-part of Ser. No. US 1999-287210, filed on 5 Apr 1999, now abandoned Continuation-in-part of Ser. No. US 1999-251370, filed on 17 Feb 1999, now abandoned Continuation-in-part of Ser. No. US 1998-127698, filed on 31 Jul 1998, now abandoned Continuation-in-part of Ser. No. US 1999-229591, filed on 13 Jan 1999, now abandoned Continuation of Ser. No. US 1998-99818, filed on 19 Jun 1998, now abandoned Continuation of Ser. No. US 127698 Continuation of Ser. No. US 99818 Continuation-in-part of Ser. No. US 1998-82364, filed on 20 May 1998, now abandoned Continuation-in-part of Ser. No. US 1998-79909, filed on 15 May 1998, now abandoned Continuation-in-part of Ser. No. US 1998-55010, filed on 3 Apr 1998, now abandoned
DT Utility
FS GRANTED
EXNAM Primary Examiner: Spector, Lorraine
LREP Marshall, Gerstein & Borun
CLMN Number of Claims: 10
ECL Exemplary Claim: 1,3
DRWN 4 Drawing Figure(s); 4 Drawing Page(s)
LN.CNT 5305
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides **nucleic acids**, the polypeptide sequences encoded by these **nucleic acids** and uses thereof. These polynucleotide and polypeptide sequences were determined to be a Interleukin-1 Receptor Antagonist. Assays for detection of the Interleukin-1 Receptor Antagonist and assays in which the antagonist is used for detection of IL-1 Receptor are also described.

L8 ANSWER 15 OF 37 USPATFULL
AN 2002:175121 USPATFULL
TI Combination of radiotherapy and anti-angiogenic factors
IN Weichselbaum, Ralph R., Chicago, IL, United States
Sukhatme, Vikas P., Newton, MA, United States
Kufe, Donald W., Wellesley, MA, United States
PA Dana Farber Cancer Institute, Inc., Boston, MA, United States (U.S. corporation)
ARCH Development Corporation, Chicago, IL, United States (U.S. corporation)
Beth Israel Deaconess Medical Center, Inc., Boston, MA, United States (U.S. corporation)
PI US 6420335 B1 20020716
AI US 1999-334084 19990616 (9)
PRAI US 1999-125566P 19990323 (60)
US 1998-89218P 19980615 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Priebe, Scott D.; Assistant Examiner: Chen, Shin-Lin
LREP Fulbright & Jaworski
CLMN Number of Claims: 28
ECL Exemplary Claim: 1
DRWN 21 Drawing Figure(s); 11 Drawing Page(s)
LN.CNT 2823
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates generally to the fields of angiogenesis and cancer therapy. More particularly, it concerns the use of anti-angiogenic factors in cancer therapy. The present invention demonstrates that angiostatin or endostatin can sensitize a cell to

radiation therapy. Methods and compositions for inhibiting growth, sensitizing a cell to radiotherapy and treating cancer growth by first inhibiting angiogenesis and then employing radiotherapy are described.

L8 ANSWER 16 OF 37 USPATFULL
AN 2002:99104 USPATFULL
TI Diagnostics for and mediators of inflammatory **disorders**
IN Parthasarathy, Sampath, Dunwoody, GA, UNITED STATES
Medford, Russell M., Atlanta, GA, UNITED STATES
Alexander, R. Wayne, Atlanta, GA, UNITED STATES
PI US 2002052000 A1 20020502
AI US 2001-779099 A1 20010207 (9)
RLI Continuation of Ser. No. US 1997-934392, filed on 19 Sep 1997, ABANDONED
PRAI US 1996-26401P 19960920 (60)
US 1997-39333P 19970317 (60)
DT Utility
FS APPLICATION
LREP Sherry M. Knowles, Esq., KING & SPALDING, 45th Floor, 191 Peachtree Street, N.E., Atlanta, GA, 30303
CLMN Number of Claims: 25
ECL Exemplary Claim: 1
DRWN 16 Drawing Page(s)
LN.CNT 1575
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A method and kit for the diagnosis and quantification of the state of oxidation, and more specifically, the level of lipid peroxidation, of a host is provided that includes contacting a host biological sample with an antibody to an antigen formed by the reaction of a lipid hydroperoxide with a primary amine. This method assesses the risk of, or existence of, oxidative damage in the host. The invention also includes monoclonal and polyclonal antibodies, as well as antibody fragments, optionally in purified or isolated form, which are useful in this method and kit.

L8 ANSWER 17 OF 37 USPATFULL
AN 2002:81614 USPATFULL
TI Interleukin--1 Hy2 materials and methods
IN Ballinger, Dennis G., Menlo Park, CA, United States
Pace, Ann M., Scotts Valley, CA, United States
Lin, Hai Shan, Castro Valley, CA, United States
PA Hyseq, Inc., Sunnyvale, CA, United States (U.S. corporation)
PI US 6372892 B1 20020416
AI US 2000-522964 20000310 (9)
RLI Continuation-in-part of Ser. No. US 1999-316086, filed on 20 May 1999, now patented, Pat. No. US 6175532
DT Utility
FS GRANTED
EXNAM Primary Examiner: Kunz, Gary L.; Assistant Examiner: Seharaseyon, J.
LREP Marshall, Gerstein, & Borun
CLMN Number of Claims: 1
ECL Exemplary Claim: 1
DRWN 4 Drawing Figure(s); 7 Drawing Page(s)
LN.CNT 4690
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides novel **nucleic acids** encoding IL-1 Hy2, a novel member of the Interleukin-1 Receptor Antagonist family, the novel polypeptides encoded by these **nucleic acids** and uses of these and related products.

L8 ANSWER 18 OF 37 USPATFULL
AN 2002:70108 USPATFULL
TI Polynucleotides encoding IL-1 Hy2 polypeptides

IN Ballinger, Dennis G., Menlo, CA, United States
Ford, John, San Mateo, CA, United States
Ho, Alice Suk-Yue, Union City, CA, United States
Lin, Hai Shan, Castro Valley, CA, United States
Pace, Ann M., Scotts Valley, CA, United States
PA Hyseq, Inc., Sunnyvale, CA, United States (U.S. corporation)
PI US 6365726 B1 20020402
AI US 2000-578458 20000522 (9)
RLI Continuation-in-part of Ser. No. US 2000-522964, filed on 10 Mar 2000
Continuation-in-part of Ser. No. US 1999-316081, filed on 20 May 1999, now patented, Pat. No. US 6339141
DT Utility
FS GRANTED
EXNAM Primary Examiner: Stucker, Jeffrey; Assistant Examiner: Seharaseyon, Jegatheesan
LREP Marshall, Gerstein & Borun.
CLMN Number of Claims: 10
ECL Exemplary Claim: 1
DRWN 7 Drawing Figure(s); 7 Drawing Page(s)
LN.CNT 4803
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides novel **nucleic acids** encoding IL-1 Hy2, a novel member of the Interleukin-1 Receptor Antagonist family, the novel polypeptides encoded by these **nucleic acids** and uses of these and related products.

L8 ANSWER 19 OF 37 USPATFULL
AN 2002:67496 USPATFULL
TI Injectable implants for tissue augmentation and restoration
IN Urry, Dan W., Birmingham, AL, UNITED STATES
PI US 2002038150 A1 20020328
AI US 2001-837969 A1 20010418 (9)
RLI Division of Ser. No. US 1999-258723, filed on 26 Feb 1999, ABANDONED
PRAI US 1998-76297P 19980227 (60)
US 1998-87155P 19980529 (60)
DT Utility
FS APPLICATION
LREP COOLEY GODWARD, LLP, 3000 EL CAMINO REAL, 5 PALO ALTO SQUARE, PALO ALTO, CA, 94306
CLMN Number of Claims: 75
ECL Exemplary Claim: 1
DRWN 6 Drawing Page(s)
LN.CNT 4162
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A method for tissue augmentation in a mammal is provided comprising injecting a polymer at a tissue site in need of augmentation and having a tissue temperature, the polymer comprising repeating peptide monomeric units selected from the group consisting of nonapeptide, pentapeptide and tetrapeptide monomeric units, wherein the monomeric units form a series of .beta.-turns separated by dynamic bridging segments suspended between the .beta.-turns, wherein the polymer has an inverse temperature transition T.sub.t less than the tissue temperature, and wherein the polymer is injected as a water solution at coacervate concentration in the substantial absence of additional water. A kit containing the injectable bioelastic polymer and a syringe is also provided.

L8 ANSWER 20 OF 37 USPATFULL
AN 2002:9923 USPATFULL
TI Interleukin-1 Hy2 materials and methods
IN Ballinger, Dennis G., Menlo Park, CA, United States
Pace, Ann M., Scots Valley, CA, United States
PA Hycey Inc., Sunnydale, CA, United States (U.S. corporation)

PI US 6339141 B1 20020115
AI US 1999-316081 19990520 (9)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Stucker, Jeffrey; Assistant Examiner: Seharaseyon, Jegatheesan
LREP Marshall, Gerstein, & Borun
CLMN Number of Claims: 4
ECL Exemplary Claim: 1
DRWN 2 Drawing Figure(s); 2 Drawing Page(s)
LN.CNT 4019
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides novel **nucleic acids** encoding IL-1 Hy2, a novel member of the Interleukin-1 Receptor Antagonist family, the novel polypeptides encoded by these **nucleic acids** and uses of these and related products.

L8 ANSWER 21 OF 37 USPATFULL
AN 2002:5759 USPATFULL
TI Interleukin-1 receptor antagonist and recombinant production thereof
IN Ford, John, San Mateo, CA, United States
Pace, Ann, Scotts Valley, CA, United States
PA Hyseq, Inc., Sunnyvale, CA, United States (U.S. corporation)
PI US 6337072 B1 20020108
AI US 1999-348942 19990707 (9)
RLI Continuation-in-part of Ser. No. US 1999-287210, filed on 5 Apr 1999, now abandoned Continuation-in-part of Ser. No. US 1999-251370, filed on 17 Feb 1999, now abandoned Continuation-in-part of Ser. No. US 1999-229591, filed on 13 Jan 1999, now abandoned Continuation-in-part of Ser. No. US 1998-127698, filed on 31 Jul 1998, now abandoned Continuation of Ser. No. US 1998-99818, filed on 19 Jun 1998, now abandoned Continuation of Ser. No. US 1998-82364, filed on 20 May 1998, now abandoned Continuation-in-part of Ser. No. US 1998-79909, filed on 15 May 1998, now abandoned Continuation-in-part of Ser. No. US 1998-55010, filed on 3 Apr 1998, now abandoned
PRAI WO 1999-US4291 19990405
DT Utility
FS GRANTED
EXNAM Primary Examiner: Spector, Lorraine
LREP Marshall, O'Toole, Gerstein, Murray & Borun
CLMN Number of Claims: 37
ECL Exemplary Claim: 1,15
DRWN 4 Drawing Figure(s); 4 Drawing Page(s)
LN.CNT 5025
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides novel **nucleic acids**, the novel polypeptide sequences encoded by these **nucleic acids** and uses thereof. These novel polynucleotide and polypeptide sequences were determined to be a novel Interleukin-1 Receptor Antagonist.

L8 ANSWER 22 OF 37 USPATFULL
AN 2001:167740 USPATFULL
TI Composition for treating benign prostatic hypertrophy
IN Gokcen, Muharrem, Minneapolis, MN, United States
Guy, Terry J., Chaska, MN, United States
PA Immunolytics, Inc., Minneapolis, MN, United States (U.S. corporation)
PI US 6296847 B1 20011002
AI US 1993-154158 19931117 (8)
RLI Continuation of Ser. No. US 1991-707662, filed on 30 May 1991, now abandoned Continuation of Ser. No. US 1989-429966, filed on 31 Oct 1989, now abandoned Continuation-in-part of Ser. No. US 1989-303809, filed on

27 Jan 1989, now abandoned
DT Utility
FS GRANTED
EXNAM Primary Examiner: Witz, Jean C.
LREP Merchant & Gould P.C.
CLMN Number of Claims: 31
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 3351
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides a composition and method for treating benign prostatic hypertrophy in mammals so as to cause the dissolution and regression of hypertrophied prostatic tissue and thereby provide relief from the obstructive symptoms associated with the **disease**. The present composition preferably comprises a sterile pyrogen-free solution of the hydrolytic enzymes collagenase and hyaluronidase, a nonionic surfactant, and an antibiotic; all provided, in a pharmaceutically acceptable, buffered, isotonic, aqueous carrier. The present method preferably comprises the direct intraprostatic injection of a safe and therapeutically effective dose of the composition via the transurethral route of administration.

L8 ANSWER 23 OF 37 USPATFULL
AN 2001:163320 USPATFULL
TI Anti-interleukin-1 receptor antagonist antibodies and uses thereof
IN Ford, John, San Mateo, CA, United States
Pace, Ann, Scotts Valley, CA, United States
PA Hyseq, Inc., Sunnyvale, CA, United States (U.S. corporation)
PI US 6294655 B1 20010925
AI US 1999-417455 19991013 (9)
RLI Continuation-in-part of Ser. No. US 1999-348942, filed on 7 Jul 1999 Continuation of Ser. No. US 1999-287210, filed on 5 Apr 1999, now abandoned Continuation-in-part of Ser. No. US 1999-251370, filed on 17 Feb 1999, now abandoned Continuation-in-part of Ser. No. US 1998-127698, filed on 31 Jul 1998, now abandoned Continuation-in-part of Ser. No. US 1999-229591, filed on 13 Jan 1999, now abandoned Continuation of Ser. No. US 1998-99818, filed on 19 Jun 1998, now abandoned , said Ser. No. US 127698 Continuation-in-part of Ser. No. US 1998-82364, filed on 20 May 1998, now abandoned , said Ser. No. US 99818 Continuation-in-part of Ser. No. US 1998-82364, filed on 20 May 1998, now abandoned Continuation-in-part of Ser. No. US 1998-79909, filed on 15 May 1998, now abandoned Continuation-in-part of Ser. No. US 1998-55010, filed on 3 Apr 1998, now abandoned
DT Utility
FS GRANTED
EXNAM Primary Examiner: Spector, Lorraine
LREP Marshall, O'Toole Gerstein, Murray & Borun
CLMN Number of Claims: 14
ECL Exemplary Claim: 1
DRWN 15 Drawing Figure(s); 14 Drawing Page(s)
LN.CNT 4656
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides novel **nucleic acids**, the novel polypeptide sequences encoded by these **nucleic acids** and uses thereof. These novel polynucleotide and polypeptide sequences were determined to be a novel Interleukin-1 Receptor Antagonist. Also provided are antibodies which bind the antagonist, methods of detecting the antagonist, and kits containing the antibodies.

L8 ANSWER 24 OF 37 USPATFULL
AN 2001:139289 USPATFULL

TI Serine protease specific monoclonal antibodies and their use
IN Kominami, Katsuya, Osaka, Japan
Okui, Akira, Yamatokoriyama-shi, Japan
Mitsui, Shinichi, Kyoto-shi, Japan
Yamaguchi, Nozomi, Kyoto-shi, Japan
PI US 2001016331 A1 20010823
AI US 2000-741171 A1 20001221 (9)
RLI Continuation-in-part of Ser. No. WO 1999-JP3578, filed on 2 Jul 1999, UNKNOWN
PRAI JP 1998-187506 19980702
DT Utility
FS APPLICATION
LREP ERIC. S. SPECTOR, JONES, TULLAR & COOPER, P.C., P.O. Box 2266 Eads Station, Arlington, VA, 22202
CLMN Number of Claims: 15
ECL Exemplary Claim: 1
DRWN 12 Drawing Page(s)
LN.CNT 1613
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A monoclonal antibody binding selectively to neurosin obtained from hybridomas, in particular, strain 2B2-6 and strain S2E5 showing stable proliferation ability. These hydridomas are obtained by fusing mouse spleen cells having a high antibody titer against neurosin with mouse-derived myeloma cells, screening fused cells being highly reactive with neurosin, and thus producing an antibody binding specifically to neurosin. By using this antibody, various **diseases** in which neurosin participates can be diagnosed.

L8 ANSWER 25 OF 37 USPATFULL
AN 2001:119148 USPATFULL
TI Polyhydroxyalkanoates for in vivo applications
IN Williams, Simon F., Sherborn, MA, United States
Martin, David P., Arlington, MA, United States
Gerngross, Tillman, Cambridge, MA, United States
Horowitz, Daniel M., Somerville, MA, United States
PI US 2001009769 A1 20010726
AI US 2001-819447 A1 20010328 (9)
RLI Division of Ser. No. US 1998-76198, filed on 12 May 1998, GRANTED, Pat. No. US 6245537
PRAI US 1997-46211P 19970512 (60)
US 1997-54289P 19970731 (60)
US 1997-63501P 19971024 (60)
US 1997-65921P 19971117 (60)
DT Utility
FS APPLICATION
LREP ARNALL GOLDEN & GREGORY, LLP, 2800 ONE ATLANTIC CENTER, 1201 WEST PEACHTREE STREET, ATLANTA, GA, 30309-3450
CLMN Number of Claims: 61
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1672
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Polyhydroxyalkanoates (PHAs) from which pyrogen has been removed are provided for use in numerous biomedical applications. PHAs which have been chemically modified to enhance physical and/or chemical properties, for targeting or to modify biodegradability or clearance by the reticuloendothelial system (RES), are described. Methods for depyrogenating PHA polymers prepared by bacterial fermentation processes are also provided, wherein pyrogens are removed from the polymers without adversely impacting the polymers' inherent chemical structures and physical properties. PHAs with advantageous processing characteristics, including low melting points and/or solubility in

non-toxic solvents, are also described. PHAs are provided which are suitable for use in in vivo applications such as in tissue coatings, stents, sutures, tubing, bone and other prostheses, bone or tissue cements, tissue regeneration devices, wound dressings, drug delivery, and for diagnostic and prophylactic uses. Properties which are selected for include degradability, elasticity, inclusion of functional groups or derivatized groups, which can in turn be used to attach targeting agents, and bioadhesion.

L8 ANSWER 26 OF 37 USPATFULL
AN 2001:86239 USPATFULL
TI Removing endotoxin with an oxdizing agent from polyhydroxyalkanoates produced by fermentation
IN Williams, Simon F., Sherborn, MA, United States
Martin, David P., Arlington, MA, United States
Gerngross, Tillman, Cambridge, MA, United States
Horowitz, Daniel M., Somerville, MA, United States
PA Metabolix, Inc., Cambridge, MA, United States (U.S. corporation)
PI US 6245537 B1 20010612
AI US 1998-76198 19980512 (9)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Naff, David M.
LREP Arnall Golden & Gregory, LLP
CLMN Number of Claims: 13
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1644
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Polyhydroxyalkanoate (PHA) that contains a pyrogen such as endotoxin due to a process of producing the PHA is treated to remove the pyrogen by a process that does not affect the inherent chemical and physical properties of the PHA to obtain a biocompatible PHA. PHA produced by fermentation with a Gram negative bacteria can be treated with an oxidizing agent such as hydrogen peroxide or benzoyl peroxide to reduce the endotoxin content to less than 20 endotoxin units/gram of PHA to produce PHA that does not elicit an acute inflammatory response when implanted in an animal. The PHA may have a melting point or glass transition temperature less than 136.degree. C., and can be chemically modified or derivatized such as by covalently coupling an attachment or targeting molecule. The PHA may be used to form various medical devices, and can be used for in vivo applications including tissue coatings, stents, sutures, tubing, bone and other prostheses, bone and tissue cements, tissue regenerating devices, wound dressings, drug delivery, and for diagnostic and prophylactic uses.

L8 ANSWER 27 OF 37 USPATFULL
AN 2001:29133 USPATFULL
TI Compositions comprising complement receptor type 1 molecules having carbohydrate structures that are selectin ligands
IN Rittershaus, Charles W., Malden, MA, United States
Toth, Carol A., Sharon, MA, United States
PA Avant Immunotherapeutics, Inc., Needham, MA, United States (U.S. corporation)
PI US 6193979 B1 20010227
AI US 1995-450274 19950525 (8)
RLI Continuation of Ser. No. WO 1994-US5285, filed on 12 May 1994
Continuation-in-part of Ser. No. US 1993-61982, filed on 17 May 1993, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Nolan, Patrick

LREP Yankwich, Leon R., O'Brien, David G.
CLMN Number of Claims: 28
ECL Exemplary Claim: 1
DRWN 8 Drawing Figure(s); 8 Drawing Page(s)
LN.CNT 3478
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides compositions comprising at least one complement moiety and at least one carbohydrate moiety, and methods of producing such compositions. In particular, the compositions of the invention comprise complement proteins related to the complement receptor type 1, and further comprise ligands for intercellular molecules, such as selectins. In a preferred embodiment, the compositions comprise a complement-related protein in combination with the Lewis X antigen or the sialyl Lewis X antigen. The compositions of the invention have use in the diagnosis or therapy of **disorders** involving complement activity and inflammation. Pharmaceutical compositions are also provided for treating or reducing inflammation mediated by inappropriate complement activity and intercellular adhesion.

L8 ANSWER 28 OF 37 USPATFULL
AN 2001:14213 USPATFULL
TI Method for diagnosing and treating chronic pelvic pain syndrome
IN Alexander, Richard B., Ellicott City, MD, United States
Ponniah, Sathibalan, Ellicott City, MD, United States
PA University of Maryland, Baltimore, Baltimore, MD, United States (U.S. corporation)
PI US 6180355 B1 20010130
AI US 1999-306927 19990507 (9)
PRAI US 1998-84668P 19980507 (60)
DT Utility
FS Granted
EXNAM Primary Examiner: Schwartzman, Robert A.; Assistant Examiner: Larson, Thomas G.
LREP Hultquist, Steven J., Barrett, William A.
CLMN Number of Claims: 14
ECL Exemplary Claim: 1
DRWN 8 Drawing Figure(s); 8 Drawing Page(s)
LN.CNT 3501
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides a superior method of diagnosing Chronic Pelvic Pain Syndrome in men comprising measuring levels of cytokines in semen or components or fractions of semen. The invention also provides a method of treating a condition associated with elevated levels of a cytokine, such as TNF-.alpha., in semen or a component or fraction thereof, comprising administering a therapeutically effective amount of an ant-cytokine compound or composition, such as an anti-TNF-.alpha. compound or composition.

L8 ANSWER 29 OF 37 USPATFULL
AN 2000:37643 USPATFULL
TI Neurotactin and uses therefor
IN Pan, Yang, Brookline, MA, United States
PA Millenium BioTherapeutics, Inc., Cambridge, MA, United States (U:S. corporation)
PI US 6043086 20000328
AI US 1998-143470 19980828 (9)
RLI Continuation-in-part of Ser. No. US 1997-991426, filed on 16 Dec 1997 which is a continuation-in-part of Ser. No. US 1997-851160, filed on 5 May 1997 which is a continuation-in-part of Ser. No. US 1996-643798, filed on 7 May 1996
DT Utility

FS Granted
EXNAM Primary Examiner: Saunders, David; Assistant Examiner: VanderVegt, F. Pierre
LREP Fish & Richardson P.C.
CLMN Number of Claims: 4
ECL Exemplary Claim: 1
DRWN 13 Drawing Figure(s); 10 Drawing Page(s)
LN.CNT 3538
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to the identification and characterization of a novel, membrane-anchored chemokine, neurotactin. Sequence analysis of neurotactin reveals that, while it includes an amino terminal domain which resembles that of other chemokines, it has an overall structure which distinguishes it from all presently identified chemokines. Neurotactin is highly expressed in normal mammalian **brain**. Inhibitors of neurotactin expression or activity can be used to treat inflammation.

L8 ANSWER 30 OF 37 USPATFULL
AN 1999:145978 USPATFULL
TI Anti-.alpha.V-integrin monoclonal antibody
IN Mitjans, Francesc, Igualada, Spain
Piulats, Jaume, Barcelona, Spain
Rosell, Elisabet, Barcelona, Spain
Adan, Jaume, Mataro, Spain
Goodman, Simon, Darmstadt, Germany, Federal Republic of
Hahn, Diane, Otzberg, Germany, Federal Republic of
PA Merck Patent Gesellschaft mit Beschrankter Haftung, Germany, Federal Republic of (non-U.S. corporation)
PI US 5985278 19991116
AI US 1995-574699 19951219 (8)
PRAI EP 1994-120165 19941220
DT Utility
FS Granted
EXNAM Primary Examiner: Chan, Christina Y.; Assistant Examiner: Gambel, Phillip
LREP Millen, White, Zelano, & Branigan, P.C.
CLMN Number of Claims: 23
ECL Exemplary Claim: 1
DRWN 52 Drawing Figure(s); 19 Drawing Page(s)
LN.CNT 1948
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to a novel monoclonal antibody, a hybridoma cell line producing said antibody, **DNA** sequences coding for said antibody, and amino acid sequences. The monoclonal antibody, a preferred embodiment of which is named 17E6, has the following properties:

reacting only with the .alpha.V-chain of human .alpha.V-integrins,

blocking the attachment to the integrin substrate of the .alpha.V-integrin bearing cell,

triggering reversal of established cell matrix interaction caused by .alpha.V-integrins,

blocking tumor **development**, and

showing no cytotoxic activity.

L8 ANSWER 31 OF 37 USPATFULL
AN 1999:136690 USPATFULL
TI Compositions comprising complement related proteins and carbohydrates,

and methods for producing and using said compositions
IN Rittershaus, Charles W., Malden, MA, United States
Toth, Carol A., Sharon, MA, United States
PA T Cell Sciences, Inc., Needham, MA, United States (U.S. corporation)
PI US 5976540 19991102
AI US 1998-61542 19980416 (9)
RLI Continuation of Ser. No. US 553339
DT Utility
FS Granted
EXNAM Primary Examiner: Achutamurthy, Ponnathapura
LREP Yankwich, Leon R.
CLMN Number of Claims: 24
ECL Exemplary Claim: 1
DRWN 8 Drawing Figure(s); 8 Drawing Page(s)
LN.CNT 3570
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides compositions comprising at least one complement moiety and at least one carbohydrate moiety, and methods of producing such compositions. In particular, the compositions of the invention comprise complement proteins related to the complement receptor type 1, and further comprise ligands for intracellular molecules, such as selectins. In a preferred embodiment, the compositions comprise a complement-related protein in combination with the Lewis X antigen or the sialyl Lewis X antigen. The compositions of the invention have use in the diagnosis or therapy of **disorders** involving complement activity and inflammation. Pharmaceutical compositions are also provided for treating or reducing inflammation mediated by inappropriate complement activity and intercellular adhesion.

L8 ANSWER 32 OF 37 USPATFULL
AN 1999:1634 USPATFULL
TI Compositions comprising complement related proteins and carbohydrates, and methods for producing and using said compositions
IN Rittershaus, Charles W., Malden, MA, United States
Toth, Carol A., Sharon, MA, United States
PA T Cell Sciences, Inc., Needham, MA, United States (U.S. corporation)
PI US 5856300 19990105
WO 9426786 19941124
AI US 1995-553339 19951113 (8)
WO 1994-US5285 19940512
19951111 PCT 371 date
19951111 PCT 102(e) date
DT Utility
FS Granted
EXNAM Primary Examiner: Achutamurthy, Ponnathapura
LREP Yankwich, Leon R., Kubinec, Jeffrey S.
CLMN Number of Claims: 37
ECL Exemplary Claim: 1,28
DRWN 8 Drawing Figure(s); 8 Drawing Page(s)
LN.CNT 3557
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides compositions comprising at least one complement moiety and at least one carbohydrate moiety, and methods of producing such compositions. In particular, the compositions of the invention comprise complement proteins related to the complement receptor type I, and further comprise ligands for intracellular molecules, such as selectins. In a preferred embodiment, the compositions comprise a complement-related protein in combination with the Louis X antigen or the sialyl Lewis X antigen. The compositions of the invention have use in the diagnosis or therapy of **disorders** involving complement activity and inflammation. Pharmaceutical

compositions are also provided for treating or reducing inflammation mediated by inappropriate complement activity and intercellular adhesion.

L8 ANSWER 33 OF 37 USPATFULL
AN 1998:68994 USPATFULL
TI Therapeutic compositions comprising a CD4 peptide and methods of treatment of HIV infections
IN Vitetta, Ellen S., Dallas, TX, United States
Uhr, Jonathan W., Dallas, TX, United States
PA Board of Regents, The University of Texas System, Austin, TX, United States (U.S. corporation)
PI US 5767072 19980616
AI US 1993-171206 19931221 (8)
RLI Continuation of Ser. No. US 1991-792212, filed on 13 Nov 1991, now abandoned which is a continuation-in-part of Ser. No. US 1990-519240, filed on 3 May 1990, now abandoned which is a continuation of Ser. No. US 1989-407479, filed on 14 Sep 1989, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Furman, Keith C.
LREP Arnold, White & Durkee
CLMN Number of Claims: 17
ECL Exemplary Claim: 1
DRWN 31 Drawing Figure(s); 18 Drawing Page(s)
LN.CNT 2853
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Disclosed are methods and compositions for the treatment of HIV infections through the specific elimination of cells which express HIV env determinants such as gp120. The compositions of the invention include toxin conjugates composed of a CD4 derived gp120 binding ligand conjugated to a toxin A chain moiety such as ricin A chain or deglycosylated ricin A chain. Where a therapeutic composition is desired, the conjugates are formed by means of a cross linker which includes a disulfide bond. Disulfide linkages are not crucial where non-therapeutic uses, such as antibody generation, is intended. In preferred aspects of the invention, conjugates incorporating shorter CD4 peptides, such as those incorporating amino acids 41-57 or 41-84 of CD4, are disclosed. Therapeutic amounts of conjugates composed of soluble CD4 or a CD4 peptide cross-linked to deglycosylated A chain by means of as SMPT linker is administered to an HIV infected patient so as to specifically eliminate HIV infected cells without exerting significant toxicity against uninfected or class II cells.

L8 ANSWER 34 OF 37 USPATFULL
AN 1998:57522 USPATFULL
TI Antibodies with specificity for a common epitope on E-selectin and L-selectin
IN Jutila, Mark A., Bozeman, MT, United States
PA The Research and Development Institute, Inc., Bozeman, MT, United States (U.S. corporation)
PI US 5756095 19980526
AI US 1995-463707 19950605 (8)
RLI Continuation of Ser. No. US 1993-64505, filed on 19 May 1993, now abandoned which is a continuation-in-part of Ser. No. US 1992-887695, filed on 22 May 1992, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Feisee, Lila; Assistant Examiner: Gambel, Phillip
LREP Morgan & Finnegan, L.L.P.
CLMN Number of Claims: 34
ECL Exemplary Claim: 1

DRWN 36 Drawing Figure(s); 23 Drawing Page(s)
LN.CNT 2567
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention involves monoclonal antibodies which recognize a common determinant found on separate and distinct adhesion molecules. The monoclonal antibodies are used for blocking cellular adhesion. Monoclonal antibodies are also described that are capable of binding to a common determinant expressed on separate and distinct selectins and in particular antibodies that bind to both E-selectin (also known as ELAM-1) and L-selectin (also known as LAM-I, LECAM-1, Leu-8, TQ-1, gp 90 MEL-14 and peripheral lymph node homing receptor). The monoclonal antibodies are useful in the diagnosis, treatment and prevention of **diseases** associated with inflammation. The monoclonal antibodies are used for detecting cells bearing selectins. Cell lines capable of producing the above described antibodies are also described.

L8 ANSWER 35 OF 37 USPATFULL
AN 97:6049 USPATFULL
TI Method of refolding human IL-13
IN Culpepper, Janice, Mountain View, CA, United States
McKenzie, Andrew, Redwood City, CA, United States
Dang, Warren, San Jose, CA, United States
Zurawski, Gerard, Redwood City, CA, United States
PA Schering Corporation, Kenilworth, NJ, United States (U.S. corporation)
PI US 5596072 19970121
AI US 1993-12543 19930201 (8)
RLI Continuation-in-part of Ser. No. US 1992-933416, filed on 21 Aug 1992, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Draper, Garnette D.; Assistant Examiner: Spector, Lorraine M.
LREP Ching, Edwin P.
CLMN Number of Claims: 10
ECL Exemplary Claim: 1
DRWN 288 Drawing Figure(s); 61 Drawing Page(s)
LN.CNT 4619
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB **Nucleic acids** encoding human IL-13, and purified IL-13 proteins and fragments thereof. Antibodies, both polyclonal and monoclonal, are also provided. Methods of using the compositions for both diagnostic and therapeutic utilities are provided.

L8 ANSWER 36 OF 37 USPATFULL
AN 94:62359 USPATFULL
TI Sialic acid binding lectin of protozoan origin
IN Pindak, Frank F., Mobile, AL, United States
Wells, David J., Mobile, AL, United States
Demes, Pavol, Bratislava, Czechoslovakia
PA South Alabama Medical Science Foundation, Mobile, AL, United States (U.S. corporation)
PI US 5330897 19940719
AI US 1992-885729 19920519 (7)
RLI Continuation-in-part of Ser. No. US 1990-626111, filed on 14 Dec 1990, now abandoned which is a continuation-in-part of Ser. No. US 1989-344923, filed on 27 Apr 1989, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Scheiner, Toni R.
LREP Sterne, Kessler, Goldstein & Fox
CLMN Number of Claims: 10
ECL Exemplary Claim: 1

DRWN No Drawings
LN.CNT 1342
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention concerns lectins isolated from the genus Tritrichomonas which bind specifically to sialic acid. The invention further pertains to uses of such lectins, and to processes for their preparation. The invention is further drawn to neuraminidase, particularly from T. mobilensis.

L8 ANSWER 37 OF 37 USPATFULL
AN 92:42541 USPATFULL
TI Method for treating benign prostatic hypertrophy
IN Gokcen, Muharrem, Minneapolis, MN, United States
Guy, Terry J., Chaska, MN, United States
PA Immunolytics, Inc., Minneapolis, MN, United States (U.S. corporation)
PI US 5116615 19920526
AI US 1991-707628 19910530 (7)
RLI Continuation of Ser. No. US 1989-429966, filed on 31 Oct 1989, now abandoned which is a continuation-in-part of Ser. No. US 1989-303809, filed on 27 Jan 1989, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Stone, Jacqueline
LREP Merchant, Gould, Smith, Edell, Welter & Schmidt
CLMN Number of Claims: 19
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 3209
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides a composition and method for treating benign prostatic hypertropy in mammals so as to cause the dissolution and regression of hypertrophied prostatic tissue and thereby provide relief from the obstructive symptoms associated with the **disease**. The present composition preferably comprises a sterile pyrogen-free solution of the hydrolytic enzymes collagenase and hyaluronidase, a nonionic surfactant, and an antibiotic; all provided, in a pharmaceutically acceptable, buffered, isotonic, aqueous carrier. The present method preferably comprises the direct intraprostatic injection of a safe and therapeutically effective dose of the composition via the transurethral route of administration.